Singular led a €23m Series A round in Spore.Bio.

Singular, a European venture firm, led a €23m Series A round in Spore.Bio, a B2B technology company, with participation from Station F, First Kind, Point 72 Ventures, Institut Pasteur, Lord David Prior, LocalGlobe, Famille C and No Label Ventures. "We are delighted to be working with such a respected group of investors too that have the technical and strategic backgrounds that will help us scale and grow Spore.Bio into a globally significant business," Amine Raji, Spore.Bio Co-Founder and CEO.